Oncology Letters · 2016 · 70 citations · 53 references
Life SciencesImmunologyOncologyCancer ImmunologyCarcinogenesisTumor ImmunologyCancer ImmunotherapyCytokine BiologyCytokines In Tumor ImmunityInflammation-associated CarcinogenesisInflammatory SignalingMacrophage BiologyBiomarkers Of Disease PrognosisCytokine Targeted TherapyDisease PrognosisMacrophage MigrationMacrophage-targeted TherapeuticsNeoplastic DiseasePrognostic Biomarker DiscoveryTumor Cell Proliferation
Macrophage migration inhibitory factor (MIF) was originally identified in 1966 by Bloom and Bennett as a pro-inflammatory cytokine involved in the inhibition of macrophage motility. Since then, studies have investigated the functional contribution of this pro-inflammatory cytokine in several immune diseases, including rheumatoid arthritis and lupus erythematous. Recently, MIF has been reported to be involved in a variety of neoplastic diseases. The present review discusses previous cancer research studies that have investigated the involvement of MIF in carcinogenesis, disease prognosis, tumor cell proliferation and invasion, and tumor-induced angiogenesis. Finally, potential therapeutic approaches based on the use of MIF antagonists and neutralizing antibodies are examined. The review concludes that MIF could be a good prognostic biomarker in several types of cancer, but also that the inhibition of MIF could represent a novel therapy against cancer.
53
Mechanism of a Reaction in Vitro Associated with Delayed-Type Hypersensitivity
Barry R. Bloom, Boyce Bennett · Science · 1966 · 1.6K citations
CD44 Is the Signaling Component of the Macrophage Migration Inhibitory Factor-CD74 Receptor Complex
Xuerong Shi, Lin Leng, Tian Wang et al. · Immunity · 2006 · 659 citations · Full text
Robert A. Mitchell, Hong Liao, Jason Chesney et al. · Proceedings of the National Academy of Sciences · 2001 · 602 citations · Full text